Skip to main content
NervGen Pharma Corp. logo

NervGen Pharma Corp. — Investor Relations & Filings

Ticker · NGEN ISIN · CA64082X2032 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 325 across all filing types
Latest filing 2026-03-31 Earnings Release
Country CA Canada
Listing TSXV NGEN

About NervGen Pharma Corp.

https://nervgen.com/

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on the discovery and development of pharmaceutical treatments designed to promote nervous system repair following neurologic trauma and disease. The company's core mission is to enable the nervous system to repair itself, offering a pharmacologic approach to conditions previously considered irreparable. Its lead drug candidate is NVG-291, a novel therapy currently in Phase 1b/2a clinical trials (CONNECT SCI Study) for individuals living with chronic spinal cord injury (SCI). Recent study data has demonstrated durable improvements in function and quality of life in this patient population. NervGen is also advancing its next-generation candidate, NVG-300, into preclinical proof-of-concept studies for three initial indications, expanding its pipeline for nervous system disorders.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Earnings Release Classification · 1% confidence The document is a press release by NervGen Pharma reporting its full year 2025 financial results with key metrics (cash, R&D, G&A expenses, net loss per share) and business updates (clinical development milestones, leadership changes, forward-looking statements). It is not a full Annual Report (10-K) but rather an earnings announcement providing high‐level financial highlights and business updates. Therefore, it fits the definition of an Earnings Release (ER). FY 2025
2026-03-31 English
News release - English.pdf
Regulatory Filings
2026-03-31 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a statutory officer certification under Canada’s NI 52-109 for venture issuers, attesting to the review and fair presentation of the issuer’s annual filings. It is not the annual report itself nor an MD&A or earnings release, but rather a regulatory compliance certificate with no specific category in the taxonomy. Therefore it falls under the fallback “Regulatory Filings” category.
2026-03-31 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a completed Form 13-502F1 submitted to the Ontario Securities Commission detailing capital values and participation fee calculations under OSC Rule 13-502 Fees. It is not an annual or interim financial report, earnings release, or management presentation, but rather a routine regulatory filing related to fee submission. This falls under the general Regulatory Filings category.
2026-03-31 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a Canadian securities commission Form 13-501F1, a mandatory participation fee submission for reporting issuers (NervGen Pharma Corp.) with market value calculations and fee amounts. It is neither an annual report, earnings release, dividend notice, management change, nor any other specific category. It is a regulatory filing with fee details, so it falls under the fallback Regulatory Filings category.
2026-03-31 English
Annual information form - English.pdf
Annual Report Classification · 1% confidence The document is an 'Annual Information Form' (AIF) for NervGen Pharma Corp. for the year ended December 31, 2025. In Canadian securities regulation, an AIF is a disclosure document that provides material information about a company, its business, and the risks it faces. While it is an annual disclosure, it is distinct from the '10-K' (which is a specific US SEC filing containing audited financial statements). Given the provided categories, '10-K' is the closest equivalent for a comprehensive annual disclosure document, although it is technically an AIF. However, since it is a primary annual regulatory disclosure document, it fits best under the 10-K category in this taxonomy. FY 2025
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.